Participated · Series A · Jul 2026

贝联珠贯的核心产品为SREAgent，基于大模型+Agent+数据构建的运维领域垂直AI Agent，用于分析历史、监控当前并预测未来以保障系统稳定运行。公司称其SREAgent能为客户提供L4级别的智能运维托管服务，面向提升运维效率并保障业务系统和硬件设备的连续稳定运行。贝联珠贯已在金融、能源、汽车、出行、零售和互联网平台等多个行业开展服务，定位为国内新一代AI Native运维服务商的领军者。创始人毕玄（林昊）领导公司，近期完成超亿元A轮融资以支持加大研发投入并推动产品在市场的规模化落地。本文未披露公司营收、用户数或估值等具体财务指标。

Participated · Series A · Jul 2026

Robopoet’s flagship product is Fuzozo, a compact plush AI companion that interacts with users through movement, conversation and emotional engagement. As of June 2026, cumulative domestic sales of Fuzozo approached 300,000 units, and during China’s 618 Shopping Festival Fuzozo sold about 40,000 units and ranked first in Tmall’s AI toy category. Robopoet began working with Tuya Smart in 2025 when Tuya supplied the AI cloud platform used by Fuzozo, helping move the product from concept into commercial production. The company is positioned to pursue international expansion with support from Tuya’s AI platform, development tools and market channels. Reporting does not disclose revenue, founding year, or location.

Participated · Series A · Jun 2026

Optolink Technology focuses on technological innovation in optical interconnection targeted at large-scale AI computing scenarios, aiming to build efficient, low-power interconnection architectures for AI computing centers. The company has developed capabilities across core optoelectronic devices, advanced packaging, and process optimization, and emphasizes independent innovation and industrial collaboration. Optolink is a flagship project incubated by Zhenzhi Venture Capital and has received sustained involvement and industrial support from Zhenzhi’s partners. Management and investors highlight the company's progress from R&D verification toward large-scale commercial deployment and mass production. The company plans to use recent proceeds to scale manufacturing, expand market presence, and continue R&D to accelerate adoption of all-optical interconnection. Public reports note the financing cycle and cumulative funding have set domestic records for startups in the optical interconnection field.

Participated · Series D · Apr 2026

Pulnovo Medical develops a Pulmonary Artery Denervation (PADN) system, a minimally invasive interventional therapy targeting over‑activated sympathetic nerve activity implicated in pulmonary vascular remodeling and cardiopulmonary disease progression. Multiple global studies and inclusion in international guidelines (including the 2022 ESC/ERS Guidelines) support PADN’s clinical benefits in improving functional capacity and reducing major adverse events. The company reports approximately 1,500 PADN procedures performed globally and regulatory approvals in seven countries, while actively promoting commercialization in the EU, Middle East, and China. In the U.S., Pulnovo has received FDA Breakthrough Device Designation and launched two fully approved IDE clinical trials led by Professor Gregg Stone. Pulnovo is pursuing further clinical evidence (including the PULSE‑LHD IDE trial) and is expanding its global clinical, regulatory, and commercial footprint, including a commercial cooperation agreement with Medtronic. The recent financing will fund continued clinical R&D, global regulatory filings, international commercialization, and investment in the core technology platform.

Participated · Series C · Apr 2026

Volant Aerotech is developing the VE25-100 “Tianxing,” its first compound-wing commercial passenger eVTOL designed for low-altitude commercial passenger service. The aircraft emphasizes a spacious cabin, flexible layouts, high payload capacity, and safety standards comparable to commercial airliners to enable high dispatch rates and all-weather operation. Volant estimates the VE25-100’s operating cost per seat per kilometer is roughly one-eighth to one-tenth that of similar helicopters. The VE25-100 has completed its full-scale maiden flight, a transition flight, and a first flight with passengers. The program has secured confirmed orders from China Southern General Aviation, Asia General Aviation, and ABC Financial Leasing, and has over 1,900 orders of intent totaling nearly ¥48 billion. Volant has had its Type Certificate application accepted by the East China Regional Administration of the CAAC and is moving toward manufacturing, certification flight testing, and mass-production readiness.